BR112015009798A2 - compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa - Google Patents

compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa

Info

Publication number
BR112015009798A2
BR112015009798A2 BR112015009798A BR112015009798A BR112015009798A2 BR 112015009798 A2 BR112015009798 A2 BR 112015009798A2 BR 112015009798 A BR112015009798 A BR 112015009798A BR 112015009798 A BR112015009798 A BR 112015009798A BR 112015009798 A2 BR112015009798 A2 BR 112015009798A2
Authority
BR
Brazil
Prior art keywords
modulating
ifnalfa
alkyl amide
substituted pyrimidine
compounds useful
Prior art date
Application number
BR112015009798A
Other languages
English (en)
Portuguese (pt)
Inventor
S Weinstein David
S Tokarski John
B Santella Joseph
M Moslin Ryan
T Wrobleski Stephen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112015009798A2 publication Critical patent/BR112015009798A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112015009798A 2012-11-08 2013-11-07 compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa BR112015009798A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723827P 2012-11-08 2012-11-08
PCT/US2013/068866 WO2014074670A1 (en) 2012-11-08 2013-11-07 ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα

Publications (1)

Publication Number Publication Date
BR112015009798A2 true BR112015009798A2 (pt) 2017-07-11

Family

ID=49667570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009798A BR112015009798A2 (pt) 2012-11-08 2013-11-07 compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa

Country Status (14)

Country Link
US (1) US9540333B2 (https=)
EP (1) EP2917186B1 (https=)
JP (1) JP6266639B2 (https=)
KR (1) KR102205914B1 (https=)
CN (1) CN104903301B (https=)
AU (1) AU2013341195B2 (https=)
BR (1) BR112015009798A2 (https=)
CA (1) CA2890935A1 (https=)
EA (1) EA028052B1 (https=)
ES (1) ES2648226T3 (https=)
IL (1) IL238605A (https=)
MX (1) MX2015005561A (https=)
SG (1) SG11201503395TA (https=)
WO (1) WO2014074670A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) * 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
KR102477063B1 (ko) * 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN107857754B (zh) * 2018-01-15 2018-11-09 泰山医学院 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2024257023A1 (en) 2023-06-14 2024-12-19 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1518855B1 (en) * 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
KR20050019797A (ko) * 2002-06-28 2005-03-03 야마노우치세이야쿠 가부시키가이샤 디아미노피리미딘카르복사미드 유도체
JP5046943B2 (ja) * 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性５−置換ピリミジン
SI1814878T1 (sl) * 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
CN101405283B (zh) * 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
WO2008009458A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
SG165655A1 (en) * 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
HRP20161310T1 (hr) * 2008-04-16 2016-12-02 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
US9139534B2 (en) * 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物

Also Published As

Publication number Publication date
WO2014074670A1 (en) 2014-05-15
AU2013341195B2 (en) 2017-09-21
EP2917186B1 (en) 2017-10-18
MX2015005561A (es) 2015-07-23
AU2013341195A1 (en) 2015-07-02
US9540333B2 (en) 2017-01-10
EP2917186A1 (en) 2015-09-16
ES2648226T3 (es) 2017-12-29
SG11201503395TA (en) 2015-05-28
US20150299139A1 (en) 2015-10-22
IL238605A0 (en) 2015-06-30
CN104903301A (zh) 2015-09-09
KR20150079678A (ko) 2015-07-08
CN104903301B (zh) 2017-08-29
CA2890935A1 (en) 2014-05-15
IL238605A (en) 2017-05-29
JP2016501185A (ja) 2016-01-18
EA201590911A1 (ru) 2015-10-30
KR102205914B1 (ko) 2021-01-20
JP6266639B2 (ja) 2018-01-24
EA028052B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
BR112015009798A2 (pt) compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa
BR112015010244A2 (pt) compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa
BR112015010102A2 (pt) compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifnalfa
EA201070786A1 (ru) Бензофуропиримидиноны
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112015022861A8 (pt) inibidores de bromodomínio
BRPI1009235A8 (pt) acetamidas substítuidas por 2-(hetero)arila, n-(hetero)arila e seus usos, e composição farmacêutica
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
UA107753C2 (xx) ЗАМІЩЕНІ ІНГІБІТОРИ АЦЕТИЛ-СоА КАРБОКСИЛАЗИ
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
EA201270216A1 (ru) Фармацевтический состав
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
PY1328356A (es) Composición herbicida que tiene actividad herbicida mejorada
MY172924A (en) Neprilysin inhibitors
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EA201171287A1 (ru) Жидкие составы солей 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
BR112012031340A2 (pt) derivados de cianoquinolina
BR112015029348A2 (pt) inibidores da bace
BR112012030482A2 (pt) tratamento de diabetes tipo 2
EA201690621A1 (ru) Полиэтиленгликольсодержащие композиции
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements